Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,299 clinical trials

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: The trial duration will be up to approximately 11 months. The treatment duration will be up to approximately 4 months (the duration …

18 years of age All Phase 1
Y Yayun Zheng

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

This study is a single-arm, single-center, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal CD19 CAR-T cells to subjects with refractory and relapsed B-cell tumors. Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by …

3 - 70 years of age All Phase N/A

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) …

18 years of age All Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

18 years of age All Phase 1

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.

18 - 75 years of age All Phase 1
X Xiangdong Cheng, Doctor

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

18 - 70 years of age All Phase 1

Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

18 - 75 years of age All Phase 1

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.

18 - 75 years of age All Phase 1/2

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic,Advanced Solid Tumors

18 - 75 years of age All Phase 1
T Timothy Yap, MBBS,PHD

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

18 years of age All Phase 1/2

Simplify language using AI